FierceBiotech57m
FDA elevates recall as Zimmer Biomet phases out hip replacement implant
The update stated that the implant’s cobalt-chromium alloy carries an increased risk of femur fractures following a procedure ...
FierceBiotech4h
FDA clears Senseonics’ 365-day Eversense CGM implant
After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...
FierceBiotech10h
Ascendis' dwarfism drug accelerates growth in phase 3, teeing up challenge to BioMarin
Ascendis Pharma has emerged as a potential threat to BioMarin’s Voxzogo, reporting phase 3 growth disorder data that exceeded ...
FierceBiotech6h
Rakovina deepens AI focus with cancer collab to select DNA-damage response kinase targets
Five months after Rakovina Therapeutics pivoted toward artificial intelligence, the cancer-focused biotech has joined forces ...
FierceBiotech8h
Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
FierceBiotech10h
Kairos goes public with $6M IPO to fund trials of lead cancer drug
With a trio of biotechs hitting the Nasdaq on Friday, it was easy to miss a smaller-scale public debut from another ...
FierceBiotech23h
PharmaLegacy acquires BTS Research in hopes of becoming a 'highly competitive global CRO'
PharmaLegacy Laboratories is snapping up BTS Research in hopes of expanding its reach as a preclinical CRO.  | PharmaLegacy ...